Quarterly triptorelin showed comparable hormonal suppression to monthly dosing in Chinese girls with central precocious puberty.

This retrospective cohort study included 70 Chinese girls diagnosed with central precocious puberty at Fuzhou First General Hospital. Participants received either quarterly triptorelin (15 mg every 90 days) or monthly triptorelin (3.75 mg every 28 days). The study assessed bone maturation, predicted adult height, and hormonal suppression as primary outcomes, alongside secondary outcomes including serum LH and FSH concentrations, uterine and ovarian volumes, BMI, and adverse events. Follow-up duration was 12 months.

Regarding hormonal suppression, serum LH levels were 0.30 ± 0.19 IU/L for the quarterly group and 0.30 ± 0.26 IU/L for the monthly group. The direction of the effect indicated comparable suppression between the two dosing schedules. P-values were not reported in the available text. Data on predicted adult height, bone maturation, and other secondary outcomes were not detailed in the provided results.

Safety and tolerability were assessed, though specific rates of adverse events, discontinuations, or serious adverse events were not reported. The study design is observational, which limits the ability to infer causality. Funding sources and potential conflicts of interest were not reported. Given the retrospective nature and lack of reported p-values or detailed safety data, clinical application should be conservative.